LEGN
Legend Biotech Corporation
Biotechnology · Healthcare · United States
20.27
close · 2026-08-13
value
78
cheaper than peers78
quality
59
stronger fundamentals59
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 3.69× | 89 |
| price to book | 3.08× | 72 |
| forward P/E | 18.77× | 53 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 56.5% | 63 |
| operating margin | -16.3% | 63 |
| return on equity | -25.2% | 61 |
| debt to equity | 40.2% | 35 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | -$55.8M |
| employees | 3,100 |
| first trade | 2020-06-05 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-11 |